The Experts below are selected from a list of 15231 Experts worldwide ranked by ideXlab platform

Kimiyoshi Tsuji - One of the best experts on this subject based on the ideXlab platform.

  • HLA Antigens are candidate markers for prediction of lymph node metastasis in gastric cancer
    Clinical & Experimental Metastasis, 1996
    Co-Authors: Kyogi Ogoshi, Tomoo Tajima, Toshio Mitomi, Kimiyoshi Tsuji
    Abstract:

    We investigated the association between human leucocyte Antigen (HLA) Antigens and lymph node metastasis in 724 gastric cancer patients. Among patients who had poorly differentiated adenocarcinoma with or without HLA-DR4 Antigen, lymph node metastasis was detected in 80.8 and 54.9%, respectively (relative risk (RR)=3.5, P = 0.0005, corrected P = 0.0285). It was more common in patients with a family history of cancer death (RR = 7.7). Among signet ring cell carcinoma patients with or without HLA-1152 Antigen, lymph node metastasis was detected in 57.7 and 19.7%, respectively (RR =5.6, P =0.0001, corrected P =0.0086). It was more common in patients who were smokers (RR = 8.3). Our findings suggest that HLA-DR4 and HLA-1152 Antigens are associated with lymph node metastasis in gastric cancer.

  • HLA‐DR4 Antigen and lymph node metastases in poorly differentiated adenocarcinoma of the stomach
    Cancer, 1994
    Co-Authors: Kyogi Ogoshi, Tomoo Tajima, Toshio Mitomi, Kimiyoshi Tsuji
    Abstract:

    Background. The authors investigated whether HLA Antigens could act as a predictor of the risk of lymph node metastasis in patients with gastric cancer. Methods. The microcytotoxicity assay was used to examine 51 HLA Antigens of the A, B, C, DR, and DQ loci in 573 patients who underwent resection of gastric cancer. The incidence of HLA Antigens in patients with or without lymph node metastasis was analyzed using the chi-square method. Results. The incidence of patients with HLA-DR4 Antigen with or without lymph node metastasis was 45.9% and 34.8%, respectively (P = 0.0098, corrected P = 0.49). The relative risk of lymph node metastasis in patients with HLA-DR4 was 1.6. In poorly differentiated adenocarcinoma, the incidence of HLA-DR4 Antigen in patients with lymph node metastasis was significantly higher (47.5%) than in patients without lymph node metastasis (18.5%), if corrected P values were tested (P = 0.0007, corrected P = 0.0387). The relative risk of lymph node metastasis in patients with poorly differentiated adenocarcinoma with DR4 was 4.0. Conclusions. The data suggest an association between the presence of HLA-DR4 and an increased risk of lymph node metastasis, especially in poorly differentiated adenocarcinoma.

  • HLA DR4 Antigen and lymph node metastases in poorly differentiated adenocarcinoma of the stomach
    Cancer, 1994
    Co-Authors: Kyogi Ogoshi, Tomoo Tajima, Toshio Mitomi, Kimiyoshi Tsuji
    Abstract:

    Background. The authors investigated whether HLA Antigens could act as a predictor of the risk of lymph node metastasis in patients with gastric cancer. Methods. The microcytotoxicity assay was used to examine 51 HLA Antigens of the A, B, C, DR, and DQ loci in 573 patients who underwent resection of gastric cancer. The incidence of HLA Antigens in patients with or without lymph node metastasis was analyzed using the chi-square method. Results. The incidence of patients with HLA-DR4 Antigen with or without lymph node metastasis was 45.9% and 34.8%, respectively (P = 0.0098, corrected P = 0.49). The relative risk of lymph node metastasis in patients with HLA-DR4 was 1.6. In poorly differentiated adenocarcinoma, the incidence of HLA-DR4 Antigen in patients with lymph node metastasis was significantly higher (47.5%) than in patients without lymph node metastasis (18.5%), if corrected P values were tested (P = 0.0007, corrected P = 0.0387). The relative risk of lymph node metastasis in patients with poorly differentiated adenocarcinoma with DR4 was 4.0. Conclusions. The data suggest an association between the presence of HLA-DR4 and an increased risk of lymph node metastasis, especially in poorly differentiated adenocarcinoma.

Eduardo Antônio Donadi - One of the best experts on this subject based on the ideXlab platform.

  • Is immunogenetic susceptibility to neuropsychiatric systemic lupus erythematosus (SLE) different from non-neuropsychiatric SLE?
    Annals of the rheumatic diseases, 1996
    Co-Authors: L. M. Silva, Eduardo Antônio Donadi
    Abstract:

    OBJECTIVES: To analyse frequency of HLA class II Antigens (DR and DQ) and lymphocytotoxic autoantibodies in patients with systemic lupus erythematosus (SLE) and subsets with or without neuropsychiatric involvement. METHODS: Ninety three patients with SLE (42 with neuropsychiatric features) were typed for HLA class II Antigens and investigated for the presence of lymphocytotoxic autoantibodies by a complement dependent microlymphocytotoxicity assay. A total of 191 controls of similar ethnic background were also typed for HLA Antigens. RESULTS: HLA-DR3 Antigen was increased in the total group of patients with SLE (p = 0.003) and in the neuropsychiatric group (p = 0.002). HLA-DR4 Antigen frequency was increased in non-neuropsychiatric patients (p = 0.001) and decreased in patients with neuropsychiatric SLE (p = 0.0005). Comparisons of HLA frequencies between subgroups of patients showed decreased HLA-DR4 (p < 0.0001) and increased HLA-DR9 and HLA-DQ2 Antigens (p = 0.0008 and 0.005 respectively) in the neuropsychiatric group. The frequency of lymphocytotoxic autoantibodies was increased in neuropsychiatric patients with SLE having HLA-DR9 specificity (p = 0.04). CONCLUSION: HLA-DR4 may have a protective specificity for the development of neuropsychiatric features of SLE and HLA-DR9, in addition to HLA-DR3, and the presence of lymphocytotoxic auto-antibodies may predispose to neuropsychiatric abnormalities.

Kyogi Ogoshi - One of the best experts on this subject based on the ideXlab platform.

  • HLA Antigens are candidate markers for prediction of lymph node metastasis in gastric cancer
    Clinical & Experimental Metastasis, 1996
    Co-Authors: Kyogi Ogoshi, Tomoo Tajima, Toshio Mitomi, Kimiyoshi Tsuji
    Abstract:

    We investigated the association between human leucocyte Antigen (HLA) Antigens and lymph node metastasis in 724 gastric cancer patients. Among patients who had poorly differentiated adenocarcinoma with or without HLA-DR4 Antigen, lymph node metastasis was detected in 80.8 and 54.9%, respectively (relative risk (RR)=3.5, P = 0.0005, corrected P = 0.0285). It was more common in patients with a family history of cancer death (RR = 7.7). Among signet ring cell carcinoma patients with or without HLA-1152 Antigen, lymph node metastasis was detected in 57.7 and 19.7%, respectively (RR =5.6, P =0.0001, corrected P =0.0086). It was more common in patients who were smokers (RR = 8.3). Our findings suggest that HLA-DR4 and HLA-1152 Antigens are associated with lymph node metastasis in gastric cancer.

  • HLA‐DR4 Antigen and lymph node metastases in poorly differentiated adenocarcinoma of the stomach
    Cancer, 1994
    Co-Authors: Kyogi Ogoshi, Tomoo Tajima, Toshio Mitomi, Kimiyoshi Tsuji
    Abstract:

    Background. The authors investigated whether HLA Antigens could act as a predictor of the risk of lymph node metastasis in patients with gastric cancer. Methods. The microcytotoxicity assay was used to examine 51 HLA Antigens of the A, B, C, DR, and DQ loci in 573 patients who underwent resection of gastric cancer. The incidence of HLA Antigens in patients with or without lymph node metastasis was analyzed using the chi-square method. Results. The incidence of patients with HLA-DR4 Antigen with or without lymph node metastasis was 45.9% and 34.8%, respectively (P = 0.0098, corrected P = 0.49). The relative risk of lymph node metastasis in patients with HLA-DR4 was 1.6. In poorly differentiated adenocarcinoma, the incidence of HLA-DR4 Antigen in patients with lymph node metastasis was significantly higher (47.5%) than in patients without lymph node metastasis (18.5%), if corrected P values were tested (P = 0.0007, corrected P = 0.0387). The relative risk of lymph node metastasis in patients with poorly differentiated adenocarcinoma with DR4 was 4.0. Conclusions. The data suggest an association between the presence of HLA-DR4 and an increased risk of lymph node metastasis, especially in poorly differentiated adenocarcinoma.

  • HLA DR4 Antigen and lymph node metastases in poorly differentiated adenocarcinoma of the stomach
    Cancer, 1994
    Co-Authors: Kyogi Ogoshi, Tomoo Tajima, Toshio Mitomi, Kimiyoshi Tsuji
    Abstract:

    Background. The authors investigated whether HLA Antigens could act as a predictor of the risk of lymph node metastasis in patients with gastric cancer. Methods. The microcytotoxicity assay was used to examine 51 HLA Antigens of the A, B, C, DR, and DQ loci in 573 patients who underwent resection of gastric cancer. The incidence of HLA Antigens in patients with or without lymph node metastasis was analyzed using the chi-square method. Results. The incidence of patients with HLA-DR4 Antigen with or without lymph node metastasis was 45.9% and 34.8%, respectively (P = 0.0098, corrected P = 0.49). The relative risk of lymph node metastasis in patients with HLA-DR4 was 1.6. In poorly differentiated adenocarcinoma, the incidence of HLA-DR4 Antigen in patients with lymph node metastasis was significantly higher (47.5%) than in patients without lymph node metastasis (18.5%), if corrected P values were tested (P = 0.0007, corrected P = 0.0387). The relative risk of lymph node metastasis in patients with poorly differentiated adenocarcinoma with DR4 was 4.0. Conclusions. The data suggest an association between the presence of HLA-DR4 and an increased risk of lymph node metastasis, especially in poorly differentiated adenocarcinoma.

L. M. Silva - One of the best experts on this subject based on the ideXlab platform.

  • Is immunogenetic susceptibility to neuropsychiatric systemic lupus erythematosus (SLE) different from non-neuropsychiatric SLE?
    Annals of the rheumatic diseases, 1996
    Co-Authors: L. M. Silva, Eduardo Antônio Donadi
    Abstract:

    OBJECTIVES: To analyse frequency of HLA class II Antigens (DR and DQ) and lymphocytotoxic autoantibodies in patients with systemic lupus erythematosus (SLE) and subsets with or without neuropsychiatric involvement. METHODS: Ninety three patients with SLE (42 with neuropsychiatric features) were typed for HLA class II Antigens and investigated for the presence of lymphocytotoxic autoantibodies by a complement dependent microlymphocytotoxicity assay. A total of 191 controls of similar ethnic background were also typed for HLA Antigens. RESULTS: HLA-DR3 Antigen was increased in the total group of patients with SLE (p = 0.003) and in the neuropsychiatric group (p = 0.002). HLA-DR4 Antigen frequency was increased in non-neuropsychiatric patients (p = 0.001) and decreased in patients with neuropsychiatric SLE (p = 0.0005). Comparisons of HLA frequencies between subgroups of patients showed decreased HLA-DR4 (p < 0.0001) and increased HLA-DR9 and HLA-DQ2 Antigens (p = 0.0008 and 0.005 respectively) in the neuropsychiatric group. The frequency of lymphocytotoxic autoantibodies was increased in neuropsychiatric patients with SLE having HLA-DR9 specificity (p = 0.04). CONCLUSION: HLA-DR4 may have a protective specificity for the development of neuropsychiatric features of SLE and HLA-DR9, in addition to HLA-DR3, and the presence of lymphocytotoxic auto-antibodies may predispose to neuropsychiatric abnormalities.

C. Masala - One of the best experts on this subject based on the ideXlab platform.

  • Valproate-induced systemic lupus erythematosus in a patient with partial trisomy of chromosome 9 and epilepsy.
    Epilepsia, 1996
    Co-Authors: Gian Luigi Gigli, Anna Scalise, Flavia Pauri, Giulia Silvestri, Marina Diomedi, Fabio Placidi, Maria Grazia Pomponi, C. Masala
    Abstract:

    Summary: We report a mentally retarded 30–year-old woman with partial trisomy of chromosome 9 (46,XX6,+der(6)t(6,9)pat) who has had epilepsy since age 11 months. She had been treated with various combinations of drugs. After 1 year of treatment with valproate (VPA) and ethosuximide (ESM), the patient developed arthral-gias, muscle weakness, fatigue, and fever. Laboratory examination showed increased sedimentation rate, hyper-gammaglobulinemia, and high titers of antinuclear antibodies (ANA). The possibility of VPA-induced systemic lupus erythematosus (SLE) was considered. This diagnosis was supported by detection of antihistone antibodies and the HLA-DR4 Antigen. VPA dosage was tapered and discontinued, with accompanying resolution of clinical, immunological and hematological signs of SLE 6 weeks after VPA discontinuation. This is the fourth reported case of VPA-induced SLE.